Great Point Partners LLC Has $11.98 Million Holdings in Autolus Therapeutics plc (NASDAQ:AUTL)

Great Point Partners LLC grew its holdings in shares of Autolus Therapeutics plc (NASDAQ:AUTL) by 195.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,441,667 shares of the company’s stock after acquiring an additional 2,275,000 shares during the quarter. Autolus Therapeutics accounts for approximately 2.3% of Great Point Partners LLC’s investment portfolio, making the stock its 21st largest position. Great Point Partners LLC owned 1.29% of Autolus Therapeutics worth $11,977,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in AUTL. Avoro Capital Advisors LLC acquired a new position in Autolus Therapeutics during the 1st quarter worth approximately $78,765,000. Price T Rowe Associates Inc. MD increased its holdings in shares of Autolus Therapeutics by 82.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company’s stock worth $35,020,000 after buying an additional 2,487,778 shares in the last quarter. Affinity Asset Advisors LLC lifted its stake in shares of Autolus Therapeutics by 117.7% in the 1st quarter. Affinity Asset Advisors LLC now owns 3,375,000 shares of the company’s stock valued at $21,532,000 after acquiring an additional 1,824,592 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Autolus Therapeutics by 74.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 2,531,688 shares of the company’s stock valued at $8,810,000 after acquiring an additional 1,080,897 shares in the last quarter. Finally, Perpetual Ltd grew its position in Autolus Therapeutics by 8.2% during the 1st quarter. Perpetual Ltd now owns 2,234,515 shares of the company’s stock worth $14,256,000 after acquiring an additional 169,784 shares during the last quarter. Institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Stock Down 6.2 %

Shares of AUTL opened at $3.50 on Tuesday. The stock’s 50-day moving average price is $4.07 and its two-hundred day moving average price is $4.37. Autolus Therapeutics plc has a 12 month low of $2.01 and a 12 month high of $7.45. The company has a market capitalization of $931.13 million, a PE ratio of -2.92 and a beta of 2.05. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.09.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). On average, analysts anticipate that Autolus Therapeutics plc will post -0.84 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on AUTL. Needham & Company LLC reissued a “buy” rating and set a $9.00 price target on shares of Autolus Therapeutics in a research note on Monday, June 17th. William Blair reiterated an “outperform” rating on shares of Autolus Therapeutics in a research report on Monday, June 3rd. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $8.70.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.